Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365870 · ClinicalTrials.gov registry record · Phase 4
Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment
A Phase 4 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02365870: Clinical Trial Phase 4 study, sponsored by Johns Hopkins University.
NCT02365870 is a Phase 4 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02365870, a Phase 4 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of the rotigotine transdermal patch in reducing anxiety in people with Parkinson's disease.
Interventions
- DRUG placebo
- DRUG rotigotine transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-08 |
| Est. Completion | 2019-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365870
The ClinicalTrials.gov registry entry for NCT02365870 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02365870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02365870 about?
NCT02365870 is a clinical study titled "Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment". This study will evaluate the effectiveness of the rotigotine transdermal patch in reducing anxiety in people with Parkinson's disease.
What is the current status of trial NCT02365870?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2016-08. Estimated completion is 2019-07.
What interventions are being tested in trial NCT02365870?
The interventions under investigation include: placebo (DRUG), rotigotine transdermal patch (DRUG).
Who is sponsoring clinical trial NCT02365870?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.